Haleon Shares Rise After GSK, Pfizer Indeminification Requests Rejected
By Scott Kanowsky Investing.com — Shares in HALEON PLC (LON:) edged higher after the consumer healthcare firm rejected requests for indemnification from GSK (LON:) and Pfizer (NYSE:) over litigation in the U.S. related to the heartburn drug, Zantac. In a statement, the U.K’s Haleon – a spin-off comprised of assets previously owned by GSK and Pfizer …
Haleon Shares Rise After GSK, Pfizer Indeminification Requests Rejected Read More »